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Abstract
Background. Cardiovascular disease is the main cause of
mortality in end-stage renal disease (ESRD) patients. Re-
cent studies have indicated that non-traditional risk factors
such as endothelial dysfunction (ED), chronic inflamma-
tion and protein-energy wasting (PEW) may contribute
significantly to the increased cardiovascular mortality
among dialysis patients. To further ascertain this associa-
tion, we carried out a cross-sectional assessment of nutri-
tional status, inflammatory markers and endothelial
dysfunction in peritoneal dialysis (PD) patients.
Methods. We measured ED functionally by flow-mediat-
ed vasodilatation (FMD) using doppler ultrasonography
and biochemically by soluble intercellular adhesion mol-
ecule-1 (sICAM-1) in 105 stable PD patients and 32
age- and sex-matched healthy controls. We also simulta-
neously measured inflammatory markers and performed
a subjective global assessment (SGA) of their nutritional
status using a seven-point scoring scale. Subjects were
subgrouped according to their nutritional and inflamma-
tory status.
Results. In PD patients, FMD was markedly lower (9.9±
4.8% vs. 16.4±4.8%, P<0.05), and sICAM-1 was signif-
icantly higher than those in controls. The malnourished
patients had signif icantly lower FMD (8.4±4.6% vs.
10.8±4.7%, P<0.05) and higher sICAM-1 than the nour-
ished patients. The inflamed group had significantly lower
FMD (7.1±3.8 vs.11.1±4.6%, P<0.05) and higher sI-
CAM-1 than the non-inflamed group. In all PD patients,
lean body mass/body weight %, albumin and SGA corre-
lated positively with FMD (r = +0.207, r = +0.224, r =
+0.285, P<0.05). However, age, log high sensitivity C-re-
active protein (hsCRP), log IL-6 and sICAM-1 were neg-
atively correlated with FMD (r= −0.275, r = −0.361, r =
−0.360, r = −0.271, P<0.05). A multiple regression anal-
ysis showed that log hsCRP was an independent factor
affecting FMD. Endothelial function, demonstrated as
FMD and sICAM-1 in the nourished PD patients with-
out inflammation, was well preserved compared to other
subgroups.
Conclusion. Our data suggest that chronic inflammation
and PEW are closely linked to ED in PD patients.
Keywords: endothelial dysfunction; inflammation; peritoneal dialysis;
protein-energy wasting
Introduction
Atherosclerotic cardiovascular disease (ACVD) is the
main cause of mortality in end-stage renal disease (ESRD)
patients, as shown in data from the US Renal Data Sys-
tem. In ESRD patients, mortality rates due to cardiovascu-
lar disease are 10 to 30 times higher than those in the
general population [1]. Moreover, there is more that attri-
butes to this high mortality rate for dialysis patients than
just traditional risk factors of ACVD such as hyperten-
sion, diabetes mellitus, cigarette smoking and dyslipidae-
mia. In this regard, it is important to analyse the
association between non-traditional risk factors, such as
inflammation, protein-energy wasting (PEW) and endo-
thelial dysfunction (ED), and the increased mortality rate
in ESRD patients [2].
PEW is the state of decreased body stores of energy
fuels such as protein and fat [3]. ESRD patients revealed
chronic inflammation, loss of blood and nutrients into di-
alysate, recurrent catabolic illness and metabolic syn-
drome resulting in loss of lean body mass (LBM). PEW
is prevalent in both predialysis and dialysis patients and
might be associated with higher rate of mortality due to
ACVD [3–5].
Inflammation, as evidenced by the elevated C-reactive
protein (CRP) and proinflammatory cytokine levels, has
been shown to predict wasting illness, cardiovascular mor-
tality, hospitalization and death in dialysis patients [2,6–11].
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ED is considered an early marker for atherosclerosis and
is associated with an increased mortality risk in patients
with both ischaemic and non-ischaemic chronic heart fail-
ure [2,10–18]. Several studies have shown that ED was im-
paired in predialysis [19,20] and dialysis patients [21–26].
Although ED was reported to be impaired in ESRD pa-
tients, any association between inflammation and nutri-
tional status in impaired endothelial function has not
been studied.
In this study, we carried out a cross-sectional study to in-
vestigate whether PEW and chronic inflammation play an
important role in ED in peritoneal dialysis (PD) patients.
Materials and methods
Subjects
This study enrolled 105 ESRD patients who had maintained PD treatment
for more than 6 months prior to this study and had been adequately dia-
lysed. We excluded those who had acute inflammation such as fever or
PD-related infection (e.g. exit site infection, tunnel infection and PD peri-
tonitis) within 2 months and patients with malignancies.
We also included healthy control subjects (n=32) who were matched
for gender and age. These control subjects did not have any history of
hypertension, diabetes mellitus, renal or vascular disease and were receiv-
ing no drugs at the start of the study.
Study procedure
This was a cross-sectional study. Subjects were checked for inflammation
markers such as high sensitivity CRP (hsCRP) and interleukin-6 (IL-6).
Simultaneously, we performed the subjective global assessment (SGA)
of the nutritional status of the subjects using a seven-point scoring scale.
ED was evaluated by flow-mediated vasodilatation (FMD) using
doppler ultrasonography and soluble intercellular adhesion molecule-1
(sICAM-1).
A medical history and a physical examination such as gender, the du-
ration of PD treatment, blood pressure, height, weight, body mass index
(BMI, kg/m2) and LBM were done. LBM was determined by creatinine
kinetics.
Blood samples were collected after at least 12 h of fasting on the day
of brachial artery FMD. We measured the level of total cholesterol, tri-
glyceride, high-density lipoprotein (HDL) cholesterol, fasting glucose,
total protein and albumin. Low-density lipoprotein (LDL) cholesterol
was calculated by the Friedewald formula. hsCRP was measured by
nephelometry. Serum IL-6 and sICAM-1 levels were measured by en-
zyme-linked immunosorbent assay (ELISA, R&D System Europe Ltd,
Abingdon, UK).
Brachial artery FMD
Patients stopped taking caffeine and any other medications, including
antihypertensive agents, at least 12 h prior to FMD assessment. Brachial
artery FMD was measured with a high-frequency (GE LOGIQ 9, 10
MHz) ultrasound scanning probe to obtain longitudinal images of the
brachial artery at a marked point 5 to 10 cm proximal to the antecubital
fossa. At first, the baseline end-diastolic diameter was measured. After
this, the cuff was inflated to 50 mmHg higher than the systolic BP and
was positioned at the proximal upper extremity. After 5 min, the cuff
was deflated, and the arterial diameter was measured 1 min after the cuff
was deflated. After 10 min, 0.6 mg of sublingual nitroglycerine was ad-
ministered, and the arterial diameter was measured 5 min later to obtain
nitroglycerine-mediated vasodilatation (NMD) to differentiate endotheli-
um-dependent from smooth-muscle effects. FMD and NMD were calcu-
lated as below.
We measured the diameter of the brachial artery on two occasions by
one observer (intra-observer variability), and another observer indepen-
dently performed the determination for the same patients (inter-observer
variability) to test the reliability of FMD measurements [27]. The intra-
observer variability was 0.06±0.04 mm, and the inter-observer variability
was 0.08±0.07 mm.
FMD (%) = [(RH-EDD) − (B-EDD)]/B-EDD × 100
NMD (%) = [(N-EDD) − (B-EDD)]/B-EDD × 100.
B-EDD, baseline end-diastolic diameter; RH-EDD, end-diastolic
diameter during reactive hyperaemia; N-EDD, nitroglycerine-induced
end-diastolic diameter; FMD, flow-mediated vasodilatation; NMD, nitro-
glycerine-mediated vasodilatation.
Subgroup analyses
Subjects were divided into subgroups according to their nutritional and
inflammatory status. Patients having hsCRP≥3.0 mg/L were grouped as
inflamed and those with an SGA score lower than 5 as malnourished. To
compare the compound effects of inflammation and PEW in patients, we
subgrouped patients according to the categories below:
N− I: nourished without inflammation, patients having hsCRP<
3.0 mg/L and SGA score >5
Table 1. Characteristics of the control group and the PD patient group
Control group
(n=32)
PD patient group
(n=105) P value
Age (years) 48.7±5.6 51.5±11.2 0.450
Sex (male:female) 14 : 18 47 : 58 0.839
PD duration (months) 87.6±49.3
ACEi or ARB use (yes, n) 79
BMI (kg/m2) 23.6±2.8 24.2±3.3 0.392
Systolic blood pressure
(mmHg)
125.0±15.4 147.7±19.7 0.000
Total cholesterol (mg/dL) 190.3±38.2 192.4±39.0 0.782
HDL cholesterol (mg/dL) 57.8±14.9 47.4±31.9 0.077
Triglyceride (mg/dL) 123.3±70.5 161.3±121.3 0.000
Fasting glucose (mg/dL) 81.1±13.2 93.3±16.0 0.000
Protein (g/dL) 7.1±0.5 6.1±0.6 0.000
Albumin (g/dL) 4.4±0.2 3.5±0.4 0.000
Log hsCRP −0.23±0.52 0.11±0.70 0.011
Log IL-6 0.13±0.37 0.83±0.28 0.000
sICAM-1 (ng/mL) 260.4±84.0 343.1±120.7 0.000
FMD (%) 16.4±4.8 9.9±4.8 0.000
NMD (%) 22.6±5.9 16.4±7.2 0.000
Data are expressed as mean±SD. Means were tested by unpaired t-test. P
values compare the control group and PD patient group. PD, peritoneal
dialysis; hsCRP, high sensitivity C-reactive protein; IL-6, interleukin-6;
sICAM-1, soluble intercellular adhesion molecule-1; FMD, flow-mediat-
ed vasodilatation; NMD, nitroglycerine-mediated vasodilatation.
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Fig. 1. Endothelium-dependent vasodilatation (FMD) and endothelium-
independent vasodilatation (NMD) of the brachial artery in the PD
patient group and the control group. FMD, flow-mediated vasodilatation;
NMD, nitroglycerine-induced vasodilatation; PD, peritoneal dialysis.
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N+I: nourished with inflammation, patients having hsCRP≥3.0 mg/L
and SGA score >5
M−I: malnourished without inflammation, patients having hsCRP<
3.0 mg/L and SGA score ≤5
M+I: malnourished with inflammation, patients having hsCRP≥
3.0 mg/L and SGA score ≤5
Statistical analysis
Statistical analysis was performed using SPSS® version 13.0 (SPSS, Chi-
cago, IL, USA). Simple comparisons of two or four groups were carried
out using an unpaired t-test or ANOVA. Pearson's correlation coefficient
was used for comparison between pairs of variables. Multiple regression
analysis was used to determine the interaction between independent vari-
ables and the influence of cofounders. Data are shown as mean±standard
deviation, unless otherwise stated. Statistical analysis of hsCRP and IL-6
was performed using log-transformed values, due to abnormal distribu-
tion. A value of P less than 0.05 was considered significant.
Results
Patients and control group
The PD patient group included 47 men and 58 women with
a mean age of 51.5±11.2 years. All patients were on a four-
to five-exchange per day PD regimen. Seventy-nine pa-
tients had taken angiotensin II-receptor blockers (ARB)
or angiotensin-converting enzyme (ACE) inhibitors.
Systolic blood pressure, fasting serum glucose and tri-
glyceride were significantly higher, whereas serum protein
and albumin levels were lower in the PD patient group
than in the control group. Log hsCRP, log IL-6, and sI-
CAM-1 levels were significantly higher in the PD patient
group than in the control group (Table 1). PD patients
were found with markedly lower FMD and NMD (9.9±
4.8% vs. 16.4±4.8%, P<0.05, 16.4±7.2% vs. 22.6±
5.9%, P<0.05) (Figure 1).
Nourished and malnourished groups in patients
Table 2 shows the clinical characteristics and biochemical
findings of the patients who were grouped by their SGA
scores. Thirty-eight patients (36.2%) were malnourished.
BMI and serum albumin levels were significantly lower
in the malnourished group. Log hsCRP and sICAM-1 le-
vels were significantly higher in the malnourished group
than in the nourished group. The malnourished group
showed significantly lower FMD and NMD values than
the nourished group (8.4±4.6% vs.10.8±4.7%, P<0.05,
14.4±6.6% vs. 17.4±7.3%, P<0.05) (Table 2).
Fig. 2. Correlation between FMD and log hsCRP levels (A), log IL-6 levels (B), sICAM-1 (C) and age (D) in the entire PD patient group.
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Non-inflamed and inflamed patient groups
Of the total, 75 patients (71.4%) had hsCRP less than 3
mg/L (‘the non-inflamed group’), whereas 30 patients
(28.6%) had hsCRP higher than 3 mg/L (‘the inflamed
group’). The inflamed group was treated with PD for a
longer period than the non-inflamed group. The inflamed
group had higher levels of age, log hsCRP, log IL-6 and
sICAM-1 and lower serum albumin and LBM/body
weight (BW) % than those in the non-inflamed group
(Table 3). Similar to the malnourished PD patients, the
inflamed group also revealed significantly lower FMD
and NMD than the non-inflamed group (7.1±3.8%
vs.11.1±4.6%, P<0.05, 14.0 ± 5.3% vs. 17.4 ± 7.7%,
P< 0.05) (Table 3).
Correlations and compound analysis affecting FMD
In Pearson's correlation analysis of the whole PD patient
group, LBM/BW%, albumin and SGA correlated positive-
ly with FMD (r = +0.207, r = +0.224, r = +0.285, P<0.05).
However, log hsCRP, log IL-6, sICAM-1 and age showed
significant negative correlations with FMD (r = −0.275,
r = −0.361, r = −0.360, r = −0.271, P<0.05) (Figure 2).
A multiple regression analysis showed that log hsCRP
was an independent factor affecting FMD (Table 4).
The subgroup analysis was performed to investigate
compound effects of the nutritional and inflammatory sta-
tus of patients. As a result, the nourished without inflam-
mation group showed the highest FMD (N− I, 11.8±
4.5%; N+I, 7.1±4.2%; M− I, 9.4±4.8%; M+I, 6.9±
3.5%; P<0.05) and the lowest sICAM-1 levels (N− I,
301.3±99.9 ng/mL; N+I, 383.5±97.3 ng/mL; M− I,
351.2±68.4 ng/mL; M+I, 429.6±193.8 ng/mL; P<0.05)
among the four subgroups. However, no significant differ-
ences were found between the group with only PEW and
the group with only inflammation (Figure 3).
Discussion
This study is the first to show the compound relationships
between the nutritional and inflammatory status and ED in
PD patients.
Annual mortality due to ACVD in ESRD patients is
10 to 30 times higher than in the general population,
even with adjusted age, gender and the presence of dia-
betes [28,29]. Traditional risk factors for ACVD such as
age, diabetes mellitus, hypertension and dyslipidaemia
are common risk factors for ESRD patients as they are
well established in the general population. However, sev-
eral studies on the association of traditional risk factors
with cardiovascular mortality in ESRD patients did not
have similar results to those in the general population.
Non-traditional risk factors for ACVD, such as PEW, in-
flammation, vascular calcification, oxidative stress and
hyperhomocysteinaemia are commonly found in chronic
renal failure patients. Based on recent studies, these fac-
tors may be closely linked to the acceleration of ACVD
in ESRD patients [30].
Table 2. Characteristics of the nourished group and the malnourished
group
Nourished
(n=67)
Malnourished
(n=38) P value
Age (years) 50.9±11.6 53.3±11.6 0.313
PD duration (months) 81.1±47.2 99.5±51.5 0.076
ACEi or ARB use (yes, n) 52 27 0.487
BMI (kg/m2) 24.7±3.1 23.3±3.3 0.029
Systolic blood pressure (mmHg) 145.6±18.3 152.5±21.7 0.095
LBM/BW % 73.8±11.0 71.9±11.5 0.423
Total cholesterol (mg/dL) 193.5±40.7 190.3±38.2 0.684
HDL cholesterol (mg/dL) 50.2±38.9 42.0±10.4 0.218
Triglyceride (mg/dL) 165.8±137.8 154.9±87.4 0.668
LDL cholesterol (mg/dL) 110.2±48.6 117.3±31.4 0.563
Fasting glucose (mg/dL) 91.9±14.2 96.8±18.8 0.139
Protein (g/dL) 6.0±0.5 5.9±0.5 0.773
Albumin (g/dL) 3.6±0.4 3.4±0.4 0.008
Log hsCRP 0.003±0.626 0.295±0.793 0.039
Log IL-6 0.799±0.230 0.909±0.327 0.095
sICAM-1 (ng/mL) 319.4±104.5 386.1±142.1 0.008
FMD (%) 10.8±4.7 8.4±4.6 0.014
NMD (%) 17.4±7.3 14.4±6.6 0.038
Data are expressed as mean±SD. Means were tested by unpaired t-test. P
values compare the nourished group and the malnourished group. LBM/
BW %, lean body mass/body weight %.
Table 4. Multiple regression analysis for the determinants of the
independent factors affecting FMD
ß P value
Lean body mass/body weight % 0.019 0.866
SGA 0.134 0.205
Albumin (g/dL) 0.086 0.410
Age (years) −0.092 0.418
Log hsCRP −0.221 0.045
sICAM-1 (ng/mL) −0.077 0.481
SGA, subjective global assessment; ß, standardized ß coefficient. The de-
pendent factor of multiple regression analysis was FMD (%).
Table 3. Characteristics of the non-inflamed group and the inflamed
group
Non-inflamed
(n=75)
Inflamed
(n=30) P value
Age (years) 49.4±56.6 56.6±11.3 0.002
PD duration (months) 79.1±44.6 110.4±54.6 0.011
ACEi or ARB use (yes, n) 58 21 0.459
BMI (kg/m2) 23.9±3.0 24.9±3.7 0.135
Systolic blood pressure (mmHg) 148.5±20.4 145.9±17.8 0.549
LBM/BW % 75.1±11.1 68.6±10.0 0.006
Total cholesterol (mg/dL) 194.2±40.9 188.1±34.0 0.463
HDL cholesterol (mg/dL) 46.5±13.4 49.6±55.9 0.649
Triglyceride (mg/dL) 156.4±123.7 173.4±116.4 0.513
LDL cholesterol (mg/dL) 116.4±38.2 103.8±52.7 0.926
Fasting glucose (mg/dL) 91.9±14.2 96.8±18.8 0.081
Protein (g/dL) 6.1±0.6 5.9±0.5 0.272
Albumin (g/dL) 3.6±0.4 3.4±0.5 0.018
Log hsCRP −0.251±0.402 1.007±0.428 0.000
Log IL-6 0.762±0.230 1.057±0.268 0.000
sICAM-1 (ng/mL) 316.9±93.3 407.3±154.1 0.000
FMD (%) 11.1±4.6 7.1±3.8 0.000
NMD (%) 17.4±7.7 14.0±5.3 0.027
Data are expressed as mean±SD. Means were tested by unpaired t-test.
P values compare the non-inflamed group and the inflamed group.
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In this study, we determined non-traditional risk factors
such as PEW, chronic inflammation and ED in PD patients
compared to in control subjects. In addition, the present
study revealed the correlations among the level of systemic
inflammatory markers, the nutritional status and ED in PD
patients.
To determine which factor influences impaired ED more
profoundly, we performed the subgroup analysis of ED ac-
cording to the nutritional and inflammation status. The sub-
group without PEWand chronic inflammation presented the
most conserved endothelial function compared to other sub-
groups. ED was not significantly different between the
groupwith only PEWand the groupwith only inflammation.
Taken together, these findings suggested that PEW and
inflammation are closely associated with the development
of ED and provided evidence that PEW, inflammation and
ED coexist in PD patients.
The important role of ED has been well demonstrated in
the pathogenesis of atherosclerosis. Endothelial function
can be assessed by monitoring the vasodilatation produced
by the administration of endothelium-dependent agonists
such as acetylcholine or by increased blood-flow shear
(as flow-mediated vasodilatation) [12,15,16].
Van Guldener C et al. first described the endothelium-
dependent vasodilatation impairment in chronic haemodia-
lysis (HD) patients [21] and in peritoneal dialysis patients
[22]. ED was reported to be correlated with coronary risk
factors such as hypertension [31,32], age [33] and hyperch-
olesterolaemia [34] in the general population. However, van
Guldener C et al. reported that ED in PD patients only cor-
related with a mean arterial pressure, not with age, gender
and total cholesterol levels. Our study showed that FMD is
significantly correlated with age but not with systolic blood
pressure and total cholesterol levels in PD patients, among
the major risk factors for coronary artery disease. Contrary
to the associations with major coronary risk factors, ED in
PD patients correlated with non-traditional coronary risk
factors such as hsCRP, IL-6, low serum albumin levels
and PEW in this study.
Thus far, the findings of endothelium-independent vaso-
dilatation have been different in chronic kidney disease
(CKD) and ESRD patients [21,22,35–39]. Van Guldener
et al. reported that endothelium-independent vasodilatation
was not different in ESRD patients compared to the control
group [21,22]. However, Joannides et al. demonstrated that
endothelium-independent vasodilatation was lower in HD
patients than in the control group [37]. These discrepancies
cannot be easily explained, but they are attributable to dif-
ferent characteristics and sizes of the study populations
and methodologies. Our study showed that endothelium-
independent vasodilatation, demonstrated as ‘NMD’, was
reduced in PD patients compared to the control group
and that it was closely associated with FMD. In particular,
both FMD and NMD were significantly lower in the mal-
nourished PD patients than the nourished PD patients. On
the other hand, the inflamed PD patients had lower FMD
and NMD than the non-inflamed PD patients did.
Although we did not investigate the vascular calcifica-
tion markers in subjects, the impairment of NMD in PD
patients seemed to imply that vascular calcification or ves-
sel stiffness played a role in the development of ED in this
study [35,40–42].
ICAM-1 was considered the reliable marker of ED [43].
Previous studies reported an association of ICAM-1 with
atherosclerotic plaque and outcome of dialysis patients
[25,26]. This study showed a significant correlation between
sICAM-1 and FMD. However, the multiple regression anal-
ysis did not show sICAM-1 as the factor affecting FMD.
In conclusion, this study showed impaired endothelial
function in PD patients in comparison with the control
group. We identified age, albumin, chronic inflammation
and PEW as being closely linked to ED in PD patients. PD
patients who had a good nutritional status and no inflamma-
tion were found with well preserved endothelial functions.
This study implied that the risk assessment integrating
non-traditional risk factors could play an important role
in predicting and designing detailed therapy strategies for
preventing ACVD mortality in ESRD patients.
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